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Abstract
Background: Although much has been published for the development of cell lines, these were lab
based and developed for scientific technical staff.
Objective of review: We present a simple and successful protocol for the development of cell
lines and tissue harvesting for the clinical scientist. We also discuss the ethical implications of tissue
retention and present a generic consent form.
Conclusion: The advantages of hospital-based cell line creation are numerous. We can be more
certain that cell lines are developed from the particular tissues of interest and accurate anatomical
and appropriate clinico-pathological control tissues are also harvested. We can also be certain of
less cell line cross contamination.
Background
In this molecular diagnostic age, we have a duty to our
patients to try to advance and improve treatment. One of
the main areas of research nowadays is related mainly to
cell cultures and their applications increases everyday [1-7].
Human cells will usually continue to grow if supplied
with the appropriate nutrients and conditions. Cell cul-
ture or cell lines helps us to investigate the physiology and
biochemistry of the cell (i.e. cell metabolism) and to test
the effect of various chemicals or drugs on specific cell
types, i.e. in vitro assays of the effect of chemotherapy,
radiotherapy and gene therapy regimes to examine the
possibility for resistance to optimise treatment. This pro-
cedure is very similar to microbiological sensitivities to
assess bacterial susceptibility to antibiotics. Furthermore
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tissue or pathological samples taken at operation can be
tested against protein chips or have their genetic material
extracted and run against gene chips. This may provide
direct prognostic information as to the likely clinical pro-
gression and response of the pathological process [1-7].
Cell lines have been used in generating artificial tissues (tis-
sue engineering), i.e. artificial skin, and to synthesize valu-
able biological compounds from large scale cell cultures,
i.e. therapeutic proteins. One of the main advantages of cell
lines is the consistency and reproducibility of results; how-
ever, cell characteristics can change after a period of contin-
uous growth. Cells are able to adapt to different culture
environments by varying the activities of their enzymes [1-
3]. A realisation of the cell's microenvironment is funda-
mental to the successful creation of cell lines. For instance
exposure of the cell culture to air allows the mixed cell cul-
ture to undergo cell mediated separation into overlying epi-
dermal cells and underlying fibroblasts without significant
chemical or physical alteration that may change cellular
behaviour (expression or multiplication).
Although much has been published for the development
of cell lines [1-7], these were lab based and developed for
scientific technical staff. We, however, present a simple
and successful protocol for the development of cell lines
and tissue harvesting for the clinical scientist. These tech-
niques do not require high technology and can be per-
formed by most clinicians in most hospitals; this will
usually require basic knowledge of cell culture concepts
(Table 1) and the materials used.
The head and neck contains the most diverse range of
accessible histopathological entities. Tissues taken are not
just tumour cell lines but mucosa and cartilage (used later
for tissue engineering). Little to date has been published
in the literature with regard to harvesting this potentially
wasted resource. We also discuss the ethics implications of
tissue retention and present a generic consent form, which
maybe adapted to suit individual institutions (see Part II).
Methods
Creation of Cell Lines
The creation of cell lines is an art, which develops with
practice and the adaptation of local resources to facilitate
tissue growth.
Primary cultures represent (heterogeneous but still closely
represent the parent cell types) freshly isolated cultures
until sub-cultured. Several sub-cultures (passages) onto
fresh media cause the cell lines either to transform
(become continuous) or die. Sub-cultured cell lines may
be different in morphology and have slight chromosomal
variation when compared to the primary cultures. Cell
lines grow attached to a solid surface but can also grow in
an unattached suspension culture in some cases. The sub-
strate used may affect cell behaviour.
The basic materials for the creation of cell lines include:
chemicals, incubators (humidified incubators 37°C – 5%
CO2 and 95% air), snap freezing materials (liquid nitro-
gen), tissue culture and some instruments (size 15 blade
scalpel and forceps) (Tables 1 and 2).
Chemicals are usually used for maintenance, as growth
media and for separation of cells explants for cell lines
(Table 2) and these procedures takes place in various uni-
versal tubes (Appendix 1).
Ethics and consent
Research and ethical approval is ideally obtained with
regards the consent and subsequent tissue use. The volun-
tary nature of the process must be emphasized and no
form of duress implied, ideally the process is carried out
well ahead of any procedure. We present our current con-
sent form for modification and usage (see Part II).
Table 1: Concepts in cell culture
Isolation of cells Cells can be isolated from tissues for ex vivo culture in several ways (purified from blood or by enzymatic digestion)
Maintaining cells in culture Cells are grown and maintained at an appropriate temperature, gas mixture and growth media (vary in pH, glucose 
concentration, growth factors, and the presence of other nutrient components) in a cell incubator. Some times 
extracellular matrix components (i.e. collagen or fibronectin) are needed to increase its adhesion
Manipulation of cultured cells Cells generally continue to divide in culture, this usually lead to nutrient depletion in the growth medium, 
Accumulation of apoptotic/necrotic cells, cell cycle arrest or promiscuous and unwanted cellular differentiation 
due to cell-to-cell contact. To avoid these problems cultured cells is manipulated. Most common manipulation: 
media changes, passaging cells, and transfecting cells
Media changes To replenish nutrients and avoid the build up of potentially harmful metabolic byproducts and dead cells by 
centrifugation or aspiration
Passaging (splitting) cells Involves transferring a small number of cells into a new vessel. This can either be done by introducing a small 
amount of culture containing a few cells diluted in a larger volume of fresh media or by a mixture of trypsin-EDTA, 
however other enzyme mixes are now available for this purpose
Transfection and transduction Involves the introduction of foreign DNA and the cells will express a protein of interest. More recently, the 
transfection of RNAi constructs have been realised as a convenient mechanism for suppressing the expression of a 
particular gene/proteinInternational Archives of Medicine 2009, 2:8 http://www.intarchmed.com/content/2/1/8
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Prospective patient data is entered on a proforma or
directly into a database detailing i.e. family history, carci-
nogenic exposure, TNM stage (with volumetric staging),
previous and proposed treatment and duration with later
entry of prognostic, morbidity and mortality data. A note
is made of the anonimised patient sample number. These
anonimised records are held in a secure computer and
written form.
Site and sampling
Controls may be selected on the basis of anatomy and/or
exposure to carcinogens or previous treatment fields, i.e.
in the head & neck region contralateral piriform fossa,
non affected portion of tissues. Control tissue can be
taken at fixed distances from the pathology edge, i.e.1, 2,
5 cm for assessment of field effect or suppressed potential
or dormant pathology clones. This is carried out with the
auspices of institutional ethics committee, research and
development department and fully informed patient con-
sent.
Each head & neck pathology must be taken into context,
i.e. assessing the exposure to potentially contaminated
body fluids, i.e. saliva, pus necessitating antimicrobial
treatment or hypoxic conditions affecting viability and
cell line growth.
A sample for histopathological confirmation of tissue type
(pathology type, grade, histology of control tissue) is also
always taken. Furthermore, confirmation of infection by
microbiological culture and later confirmation of irradica-
tion of infection (i.e. by myoplasma PCR [polymerase
chain reaction]) can be performed in house by the local
microbiological laboratory.
For non mucosal non exposed head and neck pathologies,
one hopes to sample non necrotic tissue. Here the risk of
contamination is reduced but hypoxic factors may affect
the pathological cell viability.
For mucosal (aero-digestive)/skin pathology with expo-
sure to contamination, i.e. salivary content or skin flora,
the risks of infection (i.e. mycoplasma) which may affect
tissue growth and cellular response necessitating the use
of appropriate antibiotics, antifungals or antivirals.
Tissue processing
Processing is carried out in a sterile laminar airflow envi-
ronment as is found in the typical operating theatre envi-
ronment.
Tissue can be snap frozen within seconds of excision by
full sample immersion in liquid nitrogen. Alternatively
tissue may be placed in RNA'ase later (to prevent RNA
loss) for later processing. Separate forceps and scalpel are
used for primary, secondary, metastases and control tissue
to reduce cross contamination of genetic material.
The development of cell lines from tissue explants
Pathological tissue is resected at the time of major surgery
and material surplus to pathological diagnostic require-
ments is immediately divided into three parts. The first
part (for DNA, RNA and protein extraction) is immersed
in liquid nitrogen and the second part (for later immuno-
histochemical and in situ hybridisation studies) is frozen
on dry ice and both are stored at -80°C. The third part is
used for the establishment of cell lines according to the
methodology described with monitor modifications.
Results
Collection of tissue materials and establishment of new 
cell lines
A tissue sample, where material in excess of diagnostic
requirements is available, is obtained from patients
undergoing major surgical resection with curative or pal-
liative intent. The establishment of pathological tissue cell
lines is carried out as previously described with some
modifications (Tables 1 and 2).
Biopsy material is soaked briefly in absolute alcohol (2–3
seconds) and then washed twice in DMEM containing
200 iu/ml penicillin, 200 ug/ml streptomycin and 5 ug/
ml fungizone (This is in an attempt to prevent bacterial
and fungal infections contaminating the cell lines).
Table 2: Most common chemicals used in the creation of cell lines
maintenance and growth media Dulbecco's modified Eagles medium (DMEM)-with 2 mM L-glutamine, 100 units/ml
Penicillin and 100 ug/ml streptomycin, 2.5 ug/ml
Amphotericin B (An antimicrobial cocktail to reduce chance of infection)
20% of Fetal Calf Serum- 10% v/v-decomplemented at 56'C for 45 min, 
(A growth medium containing several important growth factors)
Phosphate buffer saline (for isotonic washes and mechanical reduction in microbial load)
7% Dimethylsulfoxide (DMSO for cryo-preservation)
93% Fetal Calf Serum
separation of cells explants for cell lines Trypsin 0.05%, 0.01% bovine pancreatic trypsin 
(to allow detachment of cells from underlying substrate- plastic or collagen)
Na2EDTA
Defined keratinocyte serum free mediumInternational Archives of Medicine 2009, 2:8 http://www.intarchmed.com/content/2/1/8
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Surgical specimens are further processed in cold "estab-
lishment media" consisting of DMEM/20% FCS with 2.5
ug/ml Amphotericin-B (Antifungal agent). Tissues are
reduced to 0.5–1 mm3 fragments with crossed size 20 scal-
pel blades under aseptic conditions (this creates smaller
potential tissue explants which have a larger surface area
to volume ratio allowing the diffusion of nutrients, oxy-
gen and wastes increasing the likelihood of growth of cells
from the explant). After three washes with PBS containing
2.5 ug/ml Amphotericin-B, about 8–10 fragments are
transferred either to:
a) A 25-cm2 plastic culture flask containing not more than
3 ml of "establishment media". Cultures are maintained
in humidified incubators at 37°C in an atmosphere of 5%
CO2 and 95% air for at least four days without distur-
bance. The medium is renewed twice weekly once the tis-
sue fragments had become firmly attached. Within 7–10
days, migration of epithelial and fibroblast cells from the
pathological explants should be apparent.
b) An incubation mixture of 5 ml of trypsin type III
(SIGMA) containing 100 iu/ml penicillin, 100 ug/ml
streptomycin, and 2.5 ug/ml fungizone initially at 4°C for
12 hours and then at 37°C for 30 minutes. The digested
tissues are then resuspended in complete medium
(DMEM containing 20% FCS, 100 iu/ml penicillin, 100
ug/ml streptomycin, 2.5 ug/ml fungizone, 0.075% addi-
tional sodium bicarbonate, 0.6 mg/ml additional L-
glutamine and 0.5 ug/ml hydrocortisone) and seeded into
60 mm tissue culture Petri dishes.
All cultures are incubated in a humidified of 5% CO2/
95% air at 37°C air and the medium is changed twice
weekly. In later culture passages, cell lines are grown in
DMEM containing 10% FCS and free of all antibiotics
(this in an attempt to encourage the cell line to revert back
to a more 'natural' mode of behaviour not influenced by
the chemical properties of the antibiotics).
Fibroblast outgrowth is controlled by selective detachment
via mechanical removal using a cell-scraper or exposure to
0.05% trypsin/0.04% Na2EDTA (this allows preferential
detachment of selected cells improving the purity of the
remaining cells). After the first passage, cultures are main-
tained in DMEM/10% FCS without anti-fungal agent. Cells
then are subcultured at 95% confluence with a dilution of
1:6 to 1:8 and are stored frozen at -135°C.
New cell lines are used during passages 5–15, whereas
fibroblasts and normal keratinocytes are used at passages
3 through 5. Human keratinocytes are established from
primary cultures of normal oral mucosa and maintained
in defined keratinocyte-serum free medium (SIGMA), (as
their maintenance growth factor cf FCS).
Subculturing, maintenance and expansion of established 
cell cultures
All cell lines are cultured routinely at 37°C in a humidi-
fied atmosphere of 5% CO2 and 95% air. Cells are main-
tained in monolayer culture and passaged weekly by
incubation with 0.01% bovine pancreatic trypsin in PBS
containing 0.04% Na2EDTA for about 3–5 min at 37°C.
Detached cells were collected in DMEM/10% FCS, mixed
into a single-cell suspension in a universal and pelleted by
centrifugation in an IEC Centra-7 centrifuge for 3 minutes
at 800 g. Following resuspension in fresh, pre-warmed
medium, cell counts and viability estimation are carried
out by making a dilution of cell suspension in trypan blue
and counting using a haemocytometer counting chamber.
Cells are diluted to the required density (1–5 × 104/ml)
before plating into culture flasks (5 ml/25 cm2, 25 ml/80
cm2, 50 ml/170 cm2) or plates (200 ml/well of 96-well
plates, 2 ml/well of 24-well plates, 5 ml/well of 6-well
plates). Medium is replaced two or three times per week.
Vigilance is kept for signs of microbial infection (bacterial
or fungal), any cell aliquots that are infected should be
discarded and all apparatus sterilised.
Long term storage of cells
Cells of early passages and high viability (>80%) are
stored at -135°C in liquid nitrogen (this slows their dete-
rioration and allows later resurrection and specific experi-
mental usuage making the process overall more efficient).
Between 106-107 cells are pelleted by centrifugation and
the supernatant is discarded. The cells are resuspended in
1 ml of an ice-cold freezing mixture containing 7% DMSO
and 93% FCS and transferred to 1.5 ml cryo-tubes. After
controlled freezing, the samples are immersed in liquid
nitrogen. When required, aliquots of cells are thawed
quickly at 37°C, diluted into 20 ml DMEM/10% FCS in a
30 ml universal tube. After centrifugation, the cells are
washed once more with 20 ml of DMEM/10% FCS and
then plated out into 25 cm2 flasks. Liquid nitrogen storage
enables one to maintain a large number of cell line aliq-
uots of low passage number without the need to immor-
talise the cell lines by transfections which may change
their behaviour further away from that of the pathology of
origin. By doing this a large number of experiments can be
efficiently carried out with minimal loss of the 'natural
pathological cell' behaviour.
Sample storage
Tissue is stored in cryotubes in liquid nitrogen containers.
For material refrigerated at -80°C a back up power supply
and fail safe is essential. In either case the shelf position or
row is noted as is the numbered cryotube label with an
encryption code based on an algorithm that codes for the
unique patient identity. These anonimised records are
held in a secure computer and written form. It is essential
data is collected prospectively.International Archives of Medicine 2009, 2:8 http://www.intarchmed.com/content/2/1/8
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Head & neck cell lines
An example of some head and neck cell lines developed
using this protocol. HN1a represents primary oral tumour
whilst HN1b represents a cell lines derived from a lym-
phatic metastasis. HN2 represents a similar primary
oropharyngeal tumour (A) and secondary (B) cell line; we
also illustrate the change in morphology of the cell
depending on substrate (plastic and collagen). Note the
changed growth pattern in the metastatic cell lines (Fig-
ures 1, 2, 3, 4, 5 and 6).
Initially we were successful in 30% of cases but as experi-
ence grew, we developed cell lines in over 70% of cases.
The main difficulties tended to be infection (resolved with
strict sampling testing and cleaning of cell lines) and lack
of viability (resolved by sampling away from areas of
tumour necrosis). Fibroblast contamination was control
by differential washes and mechanical detachment.
Discussion & Conclusion
We present a simple and successful protocol for the devel-
opment of cell lines and tissue harvesting. It does not
require high technology and can be performed by most
clinical scientists in most hospitals.
The advantages of hospital based cell line creation are
numerous. We can be more certain that cell lines are
developed from the particular tissues of interest and accu-
rate anatomical and appropriate clinico-pathological con-
trol tissues are also harvested. We can also be certain of
less cell line cross contamination i.e. laboratory HELA
cells contamination of nearly over a half of all existing cell
lines which has put much previous fundamental basic sci-
ence research into question.
Modifications to this may include the use of autologous
donor serum instead of the standard fetal calf serum. Anti-
body depleted heterologous serum may even be
employed. Cells may be grown on type IV collagen or irra-
diated fibroblasts rather than plastic to better the 'in-vivo'
microenvironment of the cells. This will affect its cyto-
skeletal messenger system and eventually gene expression
and protein synthesis. Finally, as more is realized regard-
ing cell interdependency co-culture can be contemplated.
Morphological examination by phase contrast micrography in  the late log phase of growth (original magnification ×200)- HN1A oral primary (on plastic) Figure 1
Morphological examination by phase contrast 
micrography in the late log phase of growth (original 
magnification ×200)-HN1A oral primary (on plastic).
Morphological examination by phase contrast micrography in  the late log phase of growth (original magnification ×200)- HN1B metastasis (on plastic) Figure 2
Morphological examination by phase contrast 
micrography in the late log phase of growth (original 
magnification ×200)-HN1B metastasis (on plastic).
Morphological examination by phase contrast micrography in  the late log phase of growth (original magnification ×200)- HN2A oropharyngeal primary (on plastic) Figure 3
Morphological examination by phase contrast 
micrography in the late log phase of growth (original 
magnification ×200)-HN2A oropharyngeal primary 
(on plastic).International Archives of Medicine 2009, 2:8 http://www.intarchmed.com/content/2/1/8
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Essential to success is the multidisciplinary approach with
particular regards to the pathologist. Nothing should pre-
vent accurate pathological diagnosis and we prefer all
samples to be taken in full cooperation with the specialist
surgical pathologist.
Consent is also more proximate and assurance can be
given of appropriate usage.
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Appendices
Appendix 1: Most common universal tubes used in the
creation of cell lines
Culture flasks (5 ml/25 cm2, 25 ml/80 cm2, 50 ml/170
cm2)
Culture plates (200 ul/ml of 96 well plate, 2 ml/well of 24
plates, 5 ml/wel of 6 well plates)
Morphological examination by phase contrast micrography in  the late log phase of growth (original magnification ×200)- HN2B metastasis (on plastic) Figure 4
Morphological examination by phase contrast 
micrography in the late log phase of growth (original 
magnification ×200)-HN2B metastasis (on plastic).
Morphological examination by phase contrast micrography in  the late log phase of growth (original magnification ×200)- HN2A oropharyngeal primary (on collagen) Figure 5
Morphological examination by phase contrast 
micrography in the late log phase of growth (original 
magnification ×200)-HN2A oropharyngeal primary 
(on collagen).
Morphological examination by phase contrast micrography in  the late log phase of growth (original magnification ×200)- HN2B metastasis (on collagen) Figure 6
Morphological examination by phase contrast 
micrography in the late log phase of growth (original 
magnification ×200)-HN2B metastasis (on collagen).Publish with BioMed Central    and   every 
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1.5 ml cryotubes
30 ml universal tubes
25 cm2 plastic culture flasks
The flask caps allow exchange of gases with a 5% CO2
enhancement
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